Fiche centre
Optimus Medical Group
San Francisco — United States
Essais liés8clinical trials
VilleSan Franciscolocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03235479
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Elismetrep | Migraine | Phase 3 | NCT07816367 | A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | NOT_YET_RECRUITING |
| Atogepant | Migraine | Phase 3 | NCT03777059 | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine | COMPLETED |
| Atogepant | Migraine | Phase 3 | NCT03939312 | Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT03235479 | Safety and Efficacy Study in Adult Subjects With Acute Migraines | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT03461757 | Trial in Adult Subjects With Acute Migraines | COMPLETED |
| Dihydroergotamine | Migraine | Phase 3 | NCT03901482 | EMERGE — A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine | COMPLETED |
| Galcanezumab | Migraine | Phase 3 | NCT02614261 | REGAIN — Evaluation of Galcanezumab in the Prevention of Chronic Migraine | COMPLETED |
| Rimegepant | Migraine | Phase 2/3 | NCT03266588 | Open Label Safety Study in Acute Treatment of Migraine | COMPLETED |